Danaher Co. (DHR) EVP William K. Daniel Sells 131,066 Shares
Danaher Co. (NYSE:DHR) EVP William K. Daniel sold 131,066 shares of the firm’s stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $102.05, for a total value of $13,375,285.30. Following the completion of the sale, the executive vice president now directly owns 270,523 shares of the company’s stock, valued at $27,606,872.15. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Shares of Danaher Co. (DHR) opened at $95.25 on Thursday. The company has a current ratio of 1.43, a quick ratio of 1.05 and a debt-to-equity ratio of 0.39. The stock has a market capitalization of $67,361.22, a PE ratio of 26.98, a P/E/G ratio of 2.03 and a beta of 1.04. Danaher Co. has a 52-week low of $78.97 and a 52-week high of $104.82.
Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, January 30th. The conglomerate reported $1.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.16 by $0.03. The firm had revenue of $5.09 billion during the quarter, compared to the consensus estimate of $4.97 billion. Danaher had a return on equity of 11.36% and a net margin of 13.60%. The company’s quarterly revenue was up 10.9% on a year-over-year basis. During the same period last year, the company earned $1.05 EPS. analysts predict that Danaher Co. will post 4.37 earnings per share for the current fiscal year.
A number of analysts have issued reports on the company. Argus raised their target price on Danaher from $100.00 to $115.00 and gave the stock a “buy” rating in a research note on Thursday, February 1st. Royal Bank of Canada reaffirmed a “hold” rating and issued a $98.00 target price on shares of Danaher in a research note on Wednesday, January 31st. Stifel Nicolaus raised their target price on Danaher from $110.00 to $115.00 and gave the stock a “buy” rating in a research note on Wednesday, January 31st. Morgan Stanley raised their target price on Danaher from $103.00 to $110.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 31st. Finally, Credit Suisse Group raised their target price on Danaher from $99.00 to $105.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 31st. One investment analyst has rated the stock with a sell rating, five have given a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company. Danaher currently has a consensus rating of “Buy” and a consensus target price of $100.13.
Several large investors have recently modified their holdings of the stock. Calton & Associates Inc. acquired a new position in Danaher in the 4th quarter valued at about $114,000. GQG Partners LLC acquired a new position in Danaher in the 2nd quarter valued at about $101,000. First Personal Financial Services grew its position in Danaher by 128.9% in the 4th quarter. First Personal Financial Services now owns 1,227 shares of the conglomerate’s stock valued at $114,000 after acquiring an additional 691 shares in the last quarter. Zions Bancorporation grew its position in Danaher by 118.3% in the 3rd quarter. Zions Bancorporation now owns 1,231 shares of the conglomerate’s stock valued at $106,000 after acquiring an additional 667 shares in the last quarter. Finally, Resources Investment Advisors Inc. grew its position in Danaher by 661.2% in the 4th quarter. Resources Investment Advisors Inc. now owns 1,530 shares of the conglomerate’s stock valued at $142,000 after acquiring an additional 1,329 shares in the last quarter. 76.19% of the stock is owned by hedge funds and other institutional investors.
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.